Kevin P. Kerns

Array ( [id] => 10444898 [patent_doc_number] => 20150329912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-19 [patent_title] => 'BIOMARKERS IN CANCER, METHODS, AND SYSTEMS RELATED THERETO' [patent_app_type] => utility [patent_app_number] => 14/652611 [patent_app_country] => US [patent_app_date] => 2014-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21413 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14652611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9491080 [patent_doc_number] => 20140141485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR' [patent_app_type] => utility [patent_app_number] => 14/138199 [patent_app_country] => US [patent_app_date] => 2013-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 85944 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14138199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9421243 [patent_doc_number] => 20140105894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-17 [patent_title] => 'HUMANIZED ANTI-IL-18 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/133751 [patent_app_country] => US [patent_app_date] => 2013-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 16482 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14133751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9989613 [patent_doc_number] => 09034817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-19 [patent_title] => 'sgp130/Fc dimers for treatment of inflammatory disease' [patent_app_type] => utility [patent_app_number] => 14/109466 [patent_app_country] => US [patent_app_date] => 2013-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5639 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14109466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628740 [patent_doc_number] => 09346885 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Method of treating type 1 diabetes with antagonist IL-7 receptor antibodies' [patent_app_type] => utility [patent_app_number] => 14/109267 [patent_app_country] => US [patent_app_date] => 2013-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 35762 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14109267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10129257 [patent_doc_number] => 09163083 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-20 [patent_title] => 'Human oncostatin M antibodies' [patent_app_type] => utility [patent_app_number] => 14/104520 [patent_app_country] => US [patent_app_date] => 2013-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 21744 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14104520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10621675 [patent_doc_number] => 09340613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-17 [patent_title] => 'Anti-IL-6 antibodies, compositions, methods and uses' [patent_app_type] => utility [patent_app_number] => 14/096596 [patent_app_country] => US [patent_app_date] => 2013-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 45090 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 340 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14096596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001480 [patent_doc_number] => 09045558 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Nucleic acids encoding modified human thymic stromal lymphopoietin' [patent_app_type] => utility [patent_app_number] => 14/095524 [patent_app_country] => US [patent_app_date] => 2013-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12715 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14095524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396469 [patent_doc_number] => 20140093875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'MAMMALIAN CYTOKINES; RECEPTORS; RELATED REAGENTS AND METHODS' [patent_app_type] => utility [patent_app_number] => 14/094511 [patent_app_country] => US [patent_app_date] => 2013-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 25984 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14094511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9476721 [patent_doc_number] => 20140134183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-15 [patent_title] => 'BINDING MEMBERS TO IL-1 BETA' [patent_app_type] => utility [patent_app_number] => 14/072165 [patent_app_country] => US [patent_app_date] => 2013-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 23576 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14072165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10579878 [patent_doc_number] => 09301991 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-05 [patent_title] => 'sGCalphal inhibiting compositions' [patent_app_type] => utility [patent_app_number] => 14/069790 [patent_app_country] => US [patent_app_date] => 2013-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 70 [patent_no_of_words] => 24277 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14069790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9464149 [patent_doc_number] => 20140128576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-08 [patent_title] => 'Anti-IL-23 Antibodies, Compositions, Methods and Uses' [patent_app_type] => utility [patent_app_number] => 14/068670 [patent_app_country] => US [patent_app_date] => 2013-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 33837 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14068670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9331070 [patent_doc_number] => 20140057852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Treatment of Cancers with A-8R Peptide' [patent_app_type] => utility [patent_app_number] => 14/067116 [patent_app_country] => US [patent_app_date] => 2013-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 17559 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14067116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9331071 [patent_doc_number] => 20140057853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Treatment of Cancers with A-8R Peptide' [patent_app_type] => utility [patent_app_number] => 14/067084 [patent_app_country] => US [patent_app_date] => 2013-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 17560 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14067084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330103 [patent_doc_number] => 20140056885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/062026 [patent_app_country] => US [patent_app_date] => 2013-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30367 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14062026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330102 [patent_doc_number] => 20140056884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/062005 [patent_app_country] => US [patent_app_date] => 2013-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30358 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14062005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330101 [patent_doc_number] => 20140056883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/061989 [patent_app_country] => US [patent_app_date] => 2013-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30356 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14061989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10000361 [patent_doc_number] => 09044434 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Method of increasing epithelial cell proliferation with chitin binding protein' [patent_app_type] => utility [patent_app_number] => 14/060392 [patent_app_country] => US [patent_app_date] => 2013-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10514 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14060392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9435028 [patent_doc_number] => 20140112935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/057349 [patent_app_country] => US [patent_app_date] => 2013-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 16800 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14057349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12445488 [patent_doc_number] => 09981009 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Soluble Fcg receptor for treatment of autoimmune bullous diseases [patent_app_type] => utility [patent_app_number] => 15/029994 [patent_app_country] => US [patent_app_date] => 2013-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 9054 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15029994 [rel_patent_id] =>[rel_patent_doc_number] =>)